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Abstract: INTRODUCTION: Traumatic brain injury (TBI) is the most relevant external risk factor for
dementia and a major global health burden. Mild TBI (mTBI) contributes to up to 90% of all TBIs, and
the classification ”mild” often misrepresents the patient’s burden who suffer from neuropsychiatric long-
term sequelae. Magnetic resonance spectroscopy (MRS) allows in vivo detection of compromised brain
metabolism although it is not routinely used after TBI. OBJECTIVE: Thus, we performed a systematic
review and meta-analysis to elucidate if MRS has the potential to identify changes in brain metabolism in
adult patients after a single mTBI with a negative routine brain scan (CCT and/or MRI scan) compared
to aged- and sex-matched healthy controls (HC) during the acute or subacute postinjury phase (฀90
days after mTBI). METHODS: A comprehensive literature search was conducted from the first edition
of electronic databases until January 31, 2020. Group analyses were performed per metabolite using a
random-effects model. RESULTS: Four and 2 out of 5,417 articles met the inclusion criteria for the meta-
analysis and systematic review, respectively. For the meta-analysis, 50 mTBI patients and 51 HC with
a mean age of 31 and 30 years, respectively, were scanned using N-acetyl-aspartate (NAA), a marker for
neuronal integrity. Glutamate (Glu), a marker for disturbed brain metabolism, choline (Cho), a marker
for increased cell membrane turnover, and creatine (Cr) were used in 2 out of the 4 included articles.
Regions of interests were the frontal lobe, the white matter around 1 cm above the lateral ventricles,
or the whole brain. NAA was decreased in patients compared to HC with an effect size (ES) of -0.49
(95% CI -1.08 to 0.09), primarily measured in the frontal lobe. Glu was increased in the white matter
in 22 mTBI patients compared to 22 HC (ES 0.79; 95% CI 0.17-1.41). Cho was decreased in 31 mTBI
patients compared to 31 HC (ES -0.31; 95% CI -0.81 to 0.19). Cr was contradictory and, therefore,
potentially not suitable as a reference marker after mTBI. CONCLUSIONS: MRS pinpoints changes in
posttraumatic brain metabolism that correlate with cognitive dysfunction and, thus, might possibly help
to detect mTBI patients at risk for unfavorable outcome or posttraumatic neurodegeneration early.
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Abstract
Introduction: Traumatic brain injury (TBI) is the most rele-
vant external risk factor for dementia and a major global 
health burden. Mild TBI (mTBI) contributes to up to 90% of 
all TBIs, and the classification “mild” often misrepresents the 
patient’s burden who suffer from neuropsychiatric long-
term sequelae. Magnetic resonance spectroscopy (MRS) al-
lows in vivo detection of compromised brain metabolism al-
though it is not routinely used after TBI. Objective: Thus, we 
performed a systematic review and meta-analysis to eluci-
date if MRS has the potential to identify changes in brain 
metabolism in adult patients after a single mTBI with a neg-
ative routine brain scan (CCT and/or MRI scan) compared to 
aged- and sex-matched healthy controls (HC) during the 
acute or subacute postinjury phase (≤90 days after mTBI). 
Methods: A comprehensive literature search was conducted 
from the first edition of electronic databases until January 
31, 2020. Group analyses were performed per metabolite us-
ing a random-effects model. Results: Four and 2 out of 5,417 
articles met the inclusion criteria for the meta-analysis and 
systematic review, respectively. For the meta-analysis, 50 
mTBI patients and 51 HC with a mean age of 31 and 30 years, 
respectively, were scanned using N-acetyl-aspartate (NAA), 
a marker for neuronal integrity. Glutamate (Glu), a marker for 
disturbed brain metabolism, choline (Cho), a marker for in-
creased cell membrane turnover, and creatine (Cr) were 
used in 2 out of the 4 included articles. Regions of interests 
were the frontal lobe, the white matter around 1 cm above 
the lateral ventricles, or the whole brain. NAA was decreased 
in patients compared to HC with an effect size (ES) of –0.49 
(95% CI –1.08 to 0.09), primarily measured in the frontal lobe. 
Glu was increased in the white matter in 22 mTBI patients 
compared to 22 HC (ES 0.79; 95% CI 0.17–1.41). Cho was de-
creased in 31 mTBI patients compared to 31 HC (ES –0.31; 
95% CI –0.81 to 0.19). Cr was contradictory and, therefore, 
potentially not suitable as a reference marker after mTBI. 
A.E. and M.H.-S. contributed equally to this work.
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Conclusions: MRS pinpoints changes in posttraumatic brain 
metabolism that correlate with cognitive dysfunction and, 
thus, might possibly help to detect mTBI patients at risk for 
unfavorable outcome or posttraumatic neurodegeneration 
early. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Traumatic brain injury (TBI) is the most relevant ex-
ternal risk factor for dementia and shares hallmarks of 
neurodegenerative diseases, such as Alzheimer and Par-
kinson disease, and frontotemporal dementia [1–3]. Each 
year, over 50 million people sustain a TBI, which renders 
TBI the global leading cause of death and disability among 
the young and working populations. Thus, TBI is a major 
public health concern with tremendous socioeconomic 
implications and estimated costs of approximately USD 
400 billion annually [4].
Mild TBI (mTBI) accounts for 80–90% of all brain im-
pacts and is defined according to the American Congress 
of Rehabilitation Medicine (ACRM) by a score of 13–15 
on the Glasgow Coma Scale (GCS), a maximum loss of 
consciousness of 30 min, and posttraumatic amnesia 
< 24 h after the brain injury [5–7]. The term mild TBI of-
ten misrepresents the patient’s burden with functional, 
emotional, and cognitive long-term sequelae, as half of 
mTBI patients with a negative cranial computed tomog-
raphy (CCT) complain functional limitations 12 months 
after the brain impact, and up to one third suffer from 
cognitive dysfunction [8–12]. Nearly 90% of CCT or rou-
tine MRI brain scans remain negative despite major clin-
ical health concerns with the inability to return to work 
after mTBI [13–17], which emphasizes the need for ad-
ditional diagnostic tools to identify patients earlier who 
are at risk for unfavorable outcome or even posttraumat-
ic dementia. Current state-of-the-art CCT and MRI tech-
niques are limited in recognizing the full complexity of 
the mTBI neuropathology, and thus more sensitive, yet 
still realistic clinical measures to detect early compro-
mised brain metabolism that might help to predict long-
term cognitive deficits are required [16, 18].
Magnetic resonance spectroscopy (MRS) allows for in 
vivo measurement of metabolites that are undetectable by 
conventional neuroimaging thereby holding potential to 
identify mTBI patients that could benefit from specific 
neuropsychiatric and cognitive rehabilitation [19]. Brain 
energy metabolism is altered after TBI due to posttrau-
matic ischemia with mitochondrial dysfunction and loss 
of neuronal integrity with increased cell membrane turn-
over. In vivo MRS is an MRI technique that can detect 
nuclei with spins such as 1H, an abundant by-product of 
cellular respiration and brain tissue metabolites. As a 
noninvasive and safe technique, MRS is available on clin-
ical MR scanners (1.5 and 3.0 T) without ionizing radia-
tion [20]. This method holds the potential to identify 
compromised brain metabolism, but evidence after mTBI 
is scarce [21]. Key metabolites such as N-acetyl-aspartate 
(NAA), glutamate (Glu), and choline (Cho) have the po-
tential to capture the dynamic and fuller picture of the 
secondary changes occurring in the injured brain, while 
creatine (Cr) is widely recommended as a reference mark-
er (Table 1). However, its current application in TBI pa-
tients is purely analytical [22].
As it stands, there is currently no clinically available 
objective biological tool for mTBI classification beyond 
the GCS – albeit a major goal of the large TRACK-TBI 
and CENTER-TBI trials. Thus, early detection of com-
promised brain metabolism as marker for cognitive dys-
function or even the risk for posttraumatic dementia 
would be highly appreciated by clinicians to provide pa-
tients and their families with more reliable information, 
meanwhile creating a standardized protocol for TBI diag-
nosis [4, 23, 24]. With these conclusions in mind, we per-
formed a systematic review and meta-analysis to eluci-
date if MRS might be suitable to identify changes in brain 
metabolism in adult mTBI patients having a negative 
CCT and/or MRI brain scan during the acute or subacute 
postinjury phase in comparison to their age- and sex-
matched healthy controls (HC).
Materials and Methods
This systematic review and meta-analysis were performed ac-
cording to the PRISMA guidelines for systematic reviews and me-
ta-analysis [25, 26]. Eligibility was assessed according to the PICO 
(patient, intervention, control, outcome) process. We included 
original data reporting on adult mTBI patients who underwent 
MRS with an MRI field strength of 1.5 or 3 T within 90 days after 
injury (acute and subacute phase) and compared those to age- and 
sex-matched HC. Outcome measures were MRS metabolites mea-
sured in different regions of interests (ROIs). mTBI was defined 
according to the ACRM as an external head and brain impact with 
a transient or permanent focal neurological deficit and/or any al-
teration in quantitative or qualitative consciousness that does not 
exceed (i) a GCS of 13–15 after the first 30 min, (ii) a loss of con-
sciousness of 30 min, and (iii) posttraumatic amnesia < 24 h [5, 6].
Inclusion and Exclusion Criteria
We included original, English, and peer-reviewed research ar-
ticles reporting on controlled studies using MRS in adult patients 
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(≥18 years) having experienced a single mTBI (ACMR criteria) 
during the acute or subacute phase after the brain impact. Data 
were included from patients with no clinical need for a brain scan 
or with a negative CCT or MRI. At least 1 of the following metab-
olites or metabolite ratios had to be measured: NAA, Cho, Glu, Cr, 
glutamine (Gln), myoinositol (mIns), NAA/Cr, Cho/Cr, Glx (Glu/
Gln)/Cr, and mIns/Cr. Exclusion criteria were any brain pathology 
in a CCT and/or MRI scan, MRS performed beyond 90 days after 
TBI, children, patients with repetitive concussions with a previous 
TBI or any premorbidly diagnosed neurobehavioral (e.g., depres-
sion or bipolar disorder) or neurological comorbidity (e.g., sei-
zures and brain tumors), non-peer-reviewed articles, conference 
abstracts, case reports, book chapters, non-controlled studies, in-
terventional studies, animal studies, and non-English language ar-
ticles.
Search and Data Selection
A comprehensive literature search was conducted from the first 
edition of electronic databases until January 31, 2020, specifically 
through PubMed (1901 to present), ScienceDirect (2000 to pres-
ent), Cochrane Library (1991 to present), and Scopus (1980 to 
present; Fig. 1). Relevant reviews and their supplementary mate-
rial were included in full-text screening to check analyzed studies 
for eligibility as well as their reference lists to ensure that the most 
possible studies were identified. Search terms are available in the 
online supplementary Table S1 (for all online suppl. material, see 
www.karger.com/doi/10.1159/000508098). After removing dupli-
cates, all articles were screened independently in a blinded stan-
dardized manner by 2 reviewers (A.E. and M.H.-S.). Disagree-
ments on inclusion between reviewers were resolved for final deci-
sion through a detailed discussion and an additional reviewer 
(K.R.).
Risk of Bias Assessment
A risk of bias assessment was performed using a modified ver-
sion of the ROBINS-I tool [27]. Evaluation of confounding, selec-
tion, classification of intervention(s), missing data, measurement 
of outcome(s), and selection of the reported result biases were as-
sessed with either low, high, or unclear risk judgments, and the 
GRADE assessment was used to evaluate the level of evidence 
across included studies [28].
Statistical Analysis
Demographic data (sex and age) and basic characteristics (MRS 
time point after TBI, metabolites, ROIs, and MRI field strengths) 
are presented, and data are given as means ± SD and/or ranges. For 
the meta-analysis, metabolites were analyzed if applied in at least 
2 out of the 4 included studies. Statistical analysis and graphs were 
performed using Review Manager Software 5.3 (Copenhagen, 
Denmark) and R (R Core Team, Vienna, Austria), respectively 
[29]. Effect size (ES) and 95% confidence intervals (CIs) of each 
defined MRS metabolite (Table 1), namely NAA, Glu, Cho, and Cr, 
were calculated using a random-effects model according to DerSi-
monian and Laird [30].
Results
The database search returned 5,395 articles and further 
22 articles were identified from relevant reviews or refer-
ence lists (Fig. 1). After removing duplicates, 5,276 articles 
were screened by title and abstract. Thereafter, 94 full-text 
articles were assessed for eligibility. Two articles were eli-
gible for the systematic review, below indicated as study 1 
by Gasparovic et al. [24] and as study 2 by Sivák et al. [31], 
and 4 articles were eligible for the meta-analysis, namely 
study 1 [24], study 2 [31], study 3 by Veeramuthu et al. 
[32], and study 4 by Cohen et al. [33]. Studies 3 and 4 were 
not eligible for the systematic review [32, 33] due to the 
lack of subgroup analysis of CCT-negative patients.









2.02 7.5–17 Asparate + acetyl-CoA with L-aspartate 
 N-acetyltransferase enzyme or 
 N-acetylaspartylglutamate split by 
 N-acetylated-α-linked-aminodipetidase enzyme
Myelin lipid synthesis, 
 mitochondrial function, 
 neuronal viability, 
 osmoregulation
Rapid decrease 48 h after TBI; 
 disruptions to neuronal NAA occur 
due to mitochondrial dysfunction; 
increased hydrolysis of NAA to 
 provide acetate for myelin repair
NAA recovery in less severe injuries within 
days after TBI; slow or no recovery in 
 severely injured brain concomitant with 
hypoxia or hypoperfusion and consecutive 
irreversible physical and metabolic damage
Glutamate 
(Glu)
2.3 6.0–12.5 Released from vesicles and converted to Gln  
and cycled back to neurons in the Glu-Gln  
cycle; often measured through MRS as the  
combination of both molecules expressed 
as the “Glx” signal
Main excitatory 
 neurotransmitter in the 
 central nervous system
Elevated Glx signal early after TBI  
in occipital gray and parietal white 
matter
Acute increase in Glu levels correlated with 




3.24 0.5–2.5 Free choline + phosphocholine + 
 glycerophosphocholine
Marker for cell membrane 
turnover or cell destruction  
in aggressive brain tumors 
and neurodegenerative 
 diseases
Increased levels due to cellular  
damage and membrane loss
Cho levels remain elevated up to 3 months 
after moderate/severe TBI. Increased Cho 
levels during the acute phase correlated with 
poorer long-term outcome at 6–12 months
Creatine 
(Cr)
3.02 n/aa Phosphorylated from phosphocreatine (PCr) Marker for brain energy 
 metabolism, ATP synthesis, 
and regeneration
Consensus that it remains at stable 
levels following TBI, and thus used  
as a reference in metabolite ratios
n/ab
ATP, adenosine triphosphate; conc., concentration; Gln, glutamine; Glx, glutamate + glutamine; ppm, parts per million; TBI, traumatic brain injury.
a No consensus on the accepted value. 




The 2 included studies analyzed a total of 31 mTBI pa-
tients (23 males, 8 females) and 31 sex- and aged-matched 
HC (24 males, 7 females) with a mean age of 31 and 30 
years, respectively (Table 2). The mean time between TBI 
and MRS was 6.4 days (range 2.7–19 days). Metabolites 
quantified in both studies were NAA or NAA + NAA glu-
tamate, NAA/Cr, Cho, and Cr. Authors analyzed the fol-
lowing ROIs: study 1 investigated (i) the white matter 
(WM) between anterior cingulum, medial frontal gyrus, 
and superior longitudinal fasciculus, (ii) gray matter 
(GM) in the interhemispheric fissure, and (iii) the sple-
nium, while study 2 analyzed (iv) the right frontal lobe, 
(v) the left frontal lobe, and (vi) the pons (Table 2).
Gasparovic et al. [24] (study 1) found a nonsignificant 
Cho change in different ROIs. In detail, Cho was slightly 
increased compared to HC in the interhemispheric fis-
sure (GM) and in the splenium, whereas it was decreased 
in the WM, that is, 1 cm above the lateral ventricles. Cr 
was significantly increased in the WM and splenium, and 
nonsignificantly decreased in the GM. Glx was signifi-
cantly decreased in the GM, and nonsignificantly in-
creased in the WM. No significant effect was seen for 
NAA in the above-mentioned ROIs and time points, 
namely 3–19 days after mTBI.
Sivák et al. [31] (study 2) observed a significantly low-
er NAA concentration in the right and left frontal lobes. 
Lower NAA/Cr and Cho/Cr ratios were found in the right 
Records identified through database
searching (n = 5,395)
 PubMed (n = 4,762)
 Scopus (n = 332)
 ScienceDirect (n = 92)




Records after duplicates removed
(n = 5,276)
Records screened by title and abstract
(n = 5,276)




Full-text articles excluded, 
with reasons** (n = 88)
Studies included in quantitative
synthesis (meta-analysis)
(n = 4)
































*Excluded if titles and abstracts identified 
articles as conference abstracts, non-English 
language, non-magnetic resonance spectro-
scopy studies, repetitive concussion studies, 
interventional studies, animal studies, book 
chapters, and/or non-peer-reviewed studies.
**28 studies were not TBI/MRS related, 
13 examined repetitive TBI subjects or 
repetitive TBI not specified (or unable
to be extracted), 10 examined moderate and/
or severe TBI subjects, 8 had CT scan-positive/
MRI-positive subjects included (or subjects 
that could not be extracted from studies that 
examined both positive and negative subjects),
7 had not subgroup analyses for subjects of 
interest or specified the time point when MRS 
was done, 6 performed MRS only in the 
chronic stage postinjury, 6 did not define mTBI 
as GCS 13–15, LOC ≤30 min, PTA <24 h, 
5 studies were reviews, and 
5 full texts could not be retrieved.
Fig. 1. PRISMA flowchart depicting included full-text articles. Two and 4 out of 94 full-text articles were includ-
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frontal lobe. After Bonferroni’s adjustment to correct for 
multiple comparisons, NAA in the left frontal lobe and 
NAA/Cr in the right frontal lobe remained significantly 
lower in patients after mTBI compared to HC. Absolute 
Cho and Cr concentrations in the left frontal lobe tended 
to be lower in mTBI patients. 
Meta-Analysis
Four studies were included in the meta-analysis analyz-
ing 50 mTBI patients (36 males, 14 females) and 51 HC (35 
males, 16 females) with a mean age of 31 and 30 years, re-
spectively. Patients received MRS 5.5 days (mean) after the 
brain impact (Table 3). Of study 3 [32] a subgroup of CCT-
negative mTBI patients (n = 12) and of study 4 [33] a sub-
group of 7 mTBI and HC were eligible for inclusion. ROIs 
and their rationales as well as metabolites are detailed in 
Table 3. Study 2 analyzed the left and right frontal lobes 
separately, of which we used the data from the left frontal 
lobe and thereby avoided an overrepresented analysis [31]. 
Regarding measured metabolites, NAA was analyzed 
across all 4 studies, while Glu, Cho, and Cr overlapped in 
2 out of the 4 studies. MRS sequences, the localization of 
voxel placement, and voxel sizes differed across all 4 stud-
ies or were not given. Studies 1–3 used the PRESS sequence. 
Study 4 used nonlocalizing proton MRS. Voxel sizes or vol-
umes were 1 × 1 × 1 cm (study 1), 12 mL (cortex), and 9 
mL (upper brainstem) (study 2), 19 × 19 × 19 mm (study 
3), or were not specified (study 4). Within and across stud-
ies, risk of bias was low (online suppl. Table S2).
N-Acetyl-Aspartate/N-Acetyl-Aspartyl-Glutamate
Across all 4 studies, NAA showed a moderate decline 
with a moderate overall ES of –0.49 (95% CI –1.08 to 0.09) 
in 50 mTBI patients compared to 51 HC (Fig. 2). This re-
sult was mainly based on the findings of study 2, in which 
NAA was analyzed in the left frontal lobe in 21 mTBI pa-
tients (ES –1.2; 95% CI –1.85 to –0.54). In studies 1, 3, and 
4, there were no significant differences in NAA concen-
trations between mTBI patients and HC.
Glutamate
Studies 1 and 3 found increased Glu, which was pri-
marily measured in the WM of the parietal lobe in mTBI 
patients compared to HC with an overall strong ES of 
0.79 (95% CI 0.17–1.41; Fig. 3).
Choline
Studies 1 and 2 reported on decreased Cho in mTBI 
patients with a weak overall ES of –0.31 (95% CI –0.81 to 
0.19; Fig. 4).
Study ES 95% CI
Gasparovic et al., 2009
Sivák et al., 2014
Veeramuthu et al., 2018
Cohen et al., 2007
Total











–2 –1.5 –1 –0.5 0 0.5 1.0 1.5 2.0
Decrease Increase
Fig. 2. N-acetyl-aspartate (NAA) is a mark-
er for neuronal density and integrity. NAA 
moderately decreases after mTBI in com-
parison to HC with an overall ES of –0.49 
(95% CI –1.08 to 0.09), thus representing a 
moderate effect. NAA was analyzed in the 
WM 1 cm above the lateral ventricles 
(study 1), in the left frontal lobe (study 2), 
or in all brain regions (studies 3 and 4). 
Sivák et al. [31] (study 2) compared 21 
mTBI patients to 22 HC and elucidated a 
significant decrease in NAA (p = 0.002) in 
the left frontal lobe when measured 2 days 
(mean) after mTBI.
Study ES 95% CI
Gasparovic et al., 2009
Veeramuthu et al., 2018
Total







–2 –1.5 –1 –0.5 0 0.5 1.0 1.5 2.0
Decrease Increase
Fig. 3. Glutamate (Glu) is a marker for dis-
turbed brain metabolism. Two out of the 4 
included studies (studies 1 and 3) mea-
sured increased Glu in the WM 1 cm above 
the lateral ventricles at 10 h (mean) and in 
the whole brain 10.7 days (mean) after 
mTBI, respectively. The overall effect size 
was strong with 0.79 (95% CI 0.17–1.41).
Magnetic Resonance Spectroscopy 




Study 1 showed a significant increase in Cr, which was 
measured in the WM, that is, 1 cm above the lateral ven-
tricles with an ES of 0.84 (95% CI –0.11 to 1.79; Fig. 5). 
Study 2 reported a nonsignificant Cr decrease in the left 
frontal lobe with an ES of –0.77 (95% CI –1.4 to –0.15). 
These contradictory results led to an overall ES for Cr of 
–0.01 (95% CI –1.59 to 1.58).
Discussion
In this systematic review and meta-analysis, 2 and 4 out 
of 5,417 identified records were included, respectively. 
The most crucial findings were alterations in NAA and 
Glu concentrations using MRS at 3 or 1.5 T within 90 days 
after injury, i.e., during the acute and subacute phase after 
a single mTBI in adults having a CCT/MRI-negative brain 
scan. Precisely, lowered NAA and increased Glu concen-
trations were found in mTBI patients compared to HC, 
indicative for loss of neuronal integrity and disturbed 
brain metabolism [20, 24, 34]. Cho slightly decreased in 
mTBI patients, which differs to the amplified Cho concen-
trations in patients with neurodegenerative diseases and 
brain tumors as a hallmark of cell membrane turnover 
[20]. In contrast, there is evidence that Cho increases over 
time when measured in the WM but not in the GM up to 
55 days after mTBI [35], which indicates that the axonal 
pathology and precise definitions of where and when to 
measure metabolites are needed. However, the relevance 
of the overall decreased Cho measured in the GM and 
WM within study 1 and 2 during the acute and subacute 
phase after mTBI remains unclear and might be associ-
ated to the function of Cho as a precursor molecule for 
myelin. Thus, we suggest to repetitively measure Cho to 
elucidate its function over time after mTBI. Results on Cr 
concentrations in mTBI patients were contradictory and 
potentially attributed to different field strengths and ROIs. 
Moreover, a recent longitudinal study demonstrated that 
higher Cr levels in the subacute stage were positively cor-
related to cognitive impairment during the chronic stage 
after mTBI when measured in the centrum semiovale, 
thus in the WM [36]. Kirov et al. [35] found increasing Cr 
levels over time when measured in the WM but not in the 
GM up to 55 days after mTBI, which again emphasizes the 
axonal pathology after mTBI. In summary, it remains 
doubtful that Cr is a suitable reference marker following 
mTBI as previously suggested [20].
When interpreting the current results, different time 
points of MRS after mTBI must be considered especially 
as the results of NAA and Cho are mainly driven by study 
2 (Sivák et al. [31]), which measured brain metabolites 
within 33–64 h after mTBI. Thus, early MRS after mTBI 
could be favorable in detecting relevant metabolic chang-
es, and we suggest bearing this in mind for future inves-
tigations.
Study ES 95% CI
Gasparovic et al., 2009
Sivák et al., 2014
Total







–2 –1.5 –1 –0.5 0 0.5 1.0 1.5 2.0
Decrease Increase
Fig. 4. Choline (Cho) is a marker for in-
creased cell membrane turnover, and in-
creased levels in MRS detect cellular dam-
age after mTBI. Two out of the 4 included 
studies (studies 1 and 2) measured in-
creased Cho in the WM 1 cm above the lat-
eral ventricles at 10 h (mean) and in the left 
frontal lobe 2 days (mean) after mTBI, re-
spectively. The overall effect size was mod-
erate with –0.31 (95% CI –0.81 to 0.19).
Study ES 95% CI
Gasparovic et al., 2009
Sivák et al., 2014
Total







–2 –1.5 –1 –0.5 0 0.5 1.0 1.5 2.0
Decrease Increase
Fig. 5. Creatine (Cr) is currently suggested 
as a reference marker for MRS. Two out of 
the 4 included studies (studies 1 and 2) 
measured contradictory Cr results in the 
WM 1 cm above the lateral ventricles 10 h 
(mean) and in the left frontal lobe 10.7 days 
(mean) after mTBI, respectively. The over-
all effect size was very low –0.01 (95% CI 
–1.59 to 1.58), which suggests that Cr is not 
a suitable reference marker after mTBI.
Eisele/Hill-Strathy/Michels/RauenNeurodegener Dis8
DOI: 10.1159/000508098
We chose strict inclusion criteria investigating mTBI 
patients with negative routine brain scans that are often 
underdiagnosed yet still exhibit posttraumatic symptoms 
[37]. Early diagnosis of those presumably mildly brain-
injured patients at risk for long-term consequences is 
critically relevant as longitudinal follow-up studies un-
derline continued symptoms, including chronic fatigue, 
psychiatric disorders, and unsatisfied quality of life in one 
third of patients [38–41]. A recent meta-analysis revealed 
that MRS might have limitations for use in mTBI patients 
[21], which is contradictory to our findings possibly due 
to a greater heterogeneity of their study population. In 
detail, this meta-analysis defined broader inclusion crite-
ria analyzing mTBI not strictly using the ACMR guide-
lines and additionally included postconcussion patients 
during the acute, subacute, or chronic phase with or with-
out positive brain scans. This meta-analysis found no 
brain metabolite changes in these mixed mTBI and post-
concussion patients [21], most probably accentuating the 
different pathophysiology after concussion and single 
mTBI. 
Integrating the current evidence, there is a need for 
standardized temporal and spatial MRS protocols for fu-
ture research of mTBI patients.
MRS and the Link to Neurodegeneration
MRS exploits metabolic alterations in neurodegenera-
tive diseases and brain tumors [42–45], but evidence fol-
lowing mTBI is sparse. Animal studies using MRS after 
experimental TBI suggest Gln, pyruvate, glycerol, and 
phosphocholine as suitable metabolites to detect diffuse 
axonal injury and posttraumatic neurodegeneration [46–
50]. However, patients with early signs of dementia have 
exhibited reductions in Glu and NAA [51], suggesting 
that these metabolic alterations are not specific for TBI, 
but might point to the posttraumatic pathway and link to 
neurodegeneration. Moreover, NAA, Glx, and mIns cor-
related with cognitive outcomes in pediatric TBI patients 
of all severities [52]. Repetitive sport-related concussions 
result in chronic neuroinflammation and neurodegener-
ation, and MRS was previously suggested as a potential 
biomarker to detect those neurometabolic changes and 
cognitive impairment [53–57]. Microglial activation and 
chronic neuroinflammation are discussed as triggers for 
posttraumatic neurodegeneration [3, 58–60], and mIns, a 
metabolite involved in osmoregulation and astrocyte ac-
tivity, was elevated after mTBI and thus might be a prom-
ising marker [61]. Moreover, future studies should focus 
on the evident metabolic changes in mIns, mIns/Cr, and 
Glx/Cr in the putamen and, thus, in the deep GM not only 
involved in motor but also in cognitive and emotional 
circuits, particularly working memory, cognitive control, 
category learning, and emotional control, functions often 
hampered after mTBI [61].
ROIs following TBI
Our systematic review and meta-analysis brought up 
the heterogeneity of analyzed ROIs following mTBI as the 
only overlapping ROI was the frontal lobe in 3 out of the 
4 studies. In study 2, we included data of the left frontal 
lobe where NAA was most significantly decreased, and 
the hampered brain metabolism negatively correlated 
with neuropsychological performance [31]. Animal stud-
ies using MRS following experimental mTBI suggest that 
the most significant axonal damage is observed in the hip-
pocampus, thalamus, internal capsule, and corpus callo-
sum as early as 2 h after injury [62]. Thus, we suggest these 
brain regions to be considered in future trials for stan-
dardized ROIs after mTBI. To date, it is difficult to draw 
conclusions from MRS studies because ROIs are not pre-
cisely defined and often do not focus on WM well known 
to be the pathological hallmark of diffuse axonal injury 
that causes attentional and cognitive deficits after TBI 
[45].
Limitations
A limited number of articles with small sample sizes 
were eligible for inclusion. Furthermore, MRI sequences, 
field strength, voxel placements, and sizes were incongru-
ent between studies, and Cramer Rao Lower bounds cut-
offs were only given in study 3. This is necessary as a good 
signal depends mostly on voxel size, depth, and on the 
ROI (e.g., signals are less clear at borders with cerebrospi-
nal fluid or air). 
Conclusion
The strongest evidence of metabolic changes was 
found for decreased NAA and elevated Glu concentra-
tions during the acute to subacute phase in adult mTBI 
patients compared to HC, while Cr might be not suitable 
as a reference marker in mTBI patients. If these metabo-
lites have the capacity to recognize patients with negative 
routine brain scans that are at risk for posttraumatic long-
term sequelae is still not yet clear. Follow-up studies cor-
relating MRS with cognitive outcome are necessary to 
elucidate the potential of these metabolites as biomarkers 
to predict and detect posttraumatic neurodegeneration at 
an early stage.
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